Abstract
characteristics of IgA from sera of patients with IgAN Purification of IgA and controls to CD89. We found that monomeric IgA Human IgA from sera of multiple myeloma patients with of patients with IgAN showed a diminished binding IgA1 or IgA2 paraproteins was isolated by euglobulin, ZnSO 4 to CD89 compared to controls.
and (NH 4
) 2 SO 4 precipitation followed by DEAE Sephacryl (Pharmacia, Uppsala, Sweden) anion exchange chromatography, and Sephacryl S-300 (Pharmacia) gel filtration, as CD89-transfected and control cells were tested for binding creatinine clearance >80 ml/min; urinary protein <2 g/24 h. of purified IgA preparations, by FACS analysis. Cells were As controls we used serum samples from 17 matched healthy washed twice (FACS buffer) and incubated for 1 h with volunteers. Neither patients, nor controls, had symptoms or varying concentrations of purified IgA preparations, diluted signs of mucosal infection in the 2 weeks preceding the study.
Subjects and methods
in 
Cell culture
The murine B-cell line IIA1. 6 [15] was cultured in RPMI Quantification of IgA in sera 1640 medium (Life Technologies, Breda, The Netherlands) supplemented with 10% heat-inactivated FCS (Life Sera from patients with IgAN (n=23) and controls (n=17) Technologies). IIA1.6 was transfected with CD89 cDNA and were analysed for total IgA, IgA1 and IgA2 concentrations stable cell surface expression was maintained by cotrans-by ELISA using 4E8, 69-11.4, and 16-512-H5 mAbs, respectfection of human c-chain cDNA, as described previously ively [14] .
[15]. The CD89-transfectants were grown in the same medium supplemented with geneticin (G418, 0.8 mg/ml; Life Technologies) and methotrexate (MTX, 10 mmol/l; Fractionation of serum IgA
Pharmachemie, Haarlem, The Netherlands). The human monocytic like cell line, U937 was cultured in RPMI 1640 Randomly selected sera from patients with IgAN (n=6) and supplemented with 10% heat-inactivated FCS. controls (n=6) were separated by size on a 1.5×90 cm Sephacryl S300 column. Briefly, 0.5 ml aliquots of sera were diluted with an equal volume of PBS layered on the column
Detection of CD89
and fractions of 1.25 ml/6 min. were collected. The fractions were analysed for total IgA by ELISA and the binding CD89-transfected and control cells were tested for CD89 of IgA to CD89-transfected IIA1.6 cells was tested as expression by FACS analysis using CD89 mAb A77. described above. Cells (5×105) were washed twice with FACS buffer (PBS/0.5%BSA) and incubated for 1 h at 4°C with A77 
Statistical analysis
All statistical calculations were performed using SPSS (for windows, release 6.0 software package). 
Results

FACS analysis of IgA binding to nontransfected and CD89-transfected IIA1.6 cells
In order to assess binding of IgA to CD89 we used CD89-transfected IIA1.6 cells as a model [15] . These CD89-transfected IIA1.6 cells stained 100% positive for CD89 using mAb A77, whereas nontransfected cells were negative ( Figure 1A ). In agreement with this observation purified IgA bound strongly to CD89-transfected IIA1.6 cells, while hardly any binding was seen to nontransfected cells ( Figure 1A ). To confirm specificity, binding of IgA to CD89-transfected IIA1.6 cells was assessed in the presence of the inhibitory mAb My43. Addition of My43 resulted in near complete inhibition of IgA binding to (1.88±0.26 mg/ml vs 1.09±0.08 mg/ml; P<0,001) and IgA1 (1.65±0.26 mg/ml vs 1.05±0.14 mg/ml; Binding of IgA from patient and control sera to P<0,01) in their sera, while no significant differ-CD89-transfected IIA1.6 cells ence was found for IgA2 (0.25±0.02 mg/ml vs 0.20±0.02 mg/ml; P=0,17). Interestingly, the higher To assess the binding to CD89-transfected IIA1.6 cells of IgA directly from whole serum, sera from patients serum IgA concentrations in patients with IgAN did the content and ratio of polymeric, dimeric and monomeric IgA in the sera. In order to obtain insight in the effect of size on the binding to CD89 of IgA from patients with IgAN, sera of patients and controls were first fractionated by gelfiltration chromatography ( Figure 4 ). The percentages of polymeric, dimeric, and monomeric IgA, calculated from the IgA concentration in the sera samples after fractionation, were not different between patients and controls ( Table 2) . When the binding of the IgA containing fractions was assessed on CD89-transfected IIA1.6 cells, pIgA and dIgA containing fractions of patients with IgAN and Indicated is the MFI, as a measure for binding, which is calculated as described in patients and methods. not result in enhanced binding to CD89-transfected IIA1.6 cells as compared to controls ( Figure 3 ). The binding of the IgA subclasses, IgA1 and IgA2 showed no difference between patients and controls ( Table 1) .
Size fractionation of serum IgA
We demonstrated previously that purified pIgA binds better to CD89 than mIgA [9] . Therefore the amount of IgA bound to CD89 is not only determined by concentrations of IgA as described above, but also by .9 from serum of IgAN patients and controls. Sera of patients ($) with IgAN (n=23) and controls (#)(n=17) were tested for binding to CD89-transfected IIA1.6 cells. Binding of IgA was detected as Distribution of polymeric, dimeric and monomeric IgA from fractionated sera of patients with IgAN (n=6) and controls (n=6) given described in Figure 1 . Indicated is the MFI, as a measure for binding, which is calculated as described in patients and methods.
as percentages±SEM.
controls showed significantly higher MFI binding values compared to mIgA containing fractions. Interestingly, mIgA from patients with IgAN showed reduced MFI values compared to monomeric IgA from controls, even though the mIgA concentrations in the tested fractions of the patients with IgAN was~3-fold higher compared to the controls ( Figure 4) .
Binding of polymeric, dimeric, and monomeric IgA to CD89-transfected IIA1.6 cells
Next we assessed binding to CD89-transfected IIA1.6 cells of peak fractions containing pIgA, dIgA and mIgA. These fractions chosen showed no overlap in size as determined by gradient gel analysis (data not shown). First these fractions were tested at a concentration of 25 mg/ml. At these fixed concentrations, mIgA of patients with IgAN showed a strongly decreased binding to CD89 as compared to controls ( Figure 5A ). When tested in a dose response, there was a significantly (P<0.05) lower binding (MFI ) of mIgA to CD89 from patients with IgAN as compared to controls ( Figure 5B ). Binding to CD89-transfected IIA1.6 cells of dIgA and pIgA of patients was not significantly reduced as compared to dIgA and pIgA of controls ( Figure 5C ).
Binding and inhibition of IgA to U937
To exclude that the observed differences were caused by the cell-transfectant, similar experiments were performed with cells which naturally express CD89. For this purpose the monocytic like cell line U937 was used. Control experiments showed a significant expression of CD89 on U937 and binding of purified IgA which was completely inhibited by MY43 (data not shown). When purified fractions of monomeric IgA from patients and controls was tested for binding, we also found a significantly reduced binding of mIgA from IgAN patients (data not shown). The reduced binding of mIgA to CD89 might lead to a reduced interference with pIgA binding and therefore favour pIgA deposition via CD89 interaction. To assess the capacity of mIgA from patients with IgAN and controls to interfere with binding of pIgA, U937 cells were pre-incubated with purified fractions of In this study we assessed the binding of IgA of different sizes to IIA1.6 cells transfected with human CD89. We used either purified IgA or IgA directly from patient binding. This was found both for control sera and for sera of IgAN patients. Therefore we think it is unlikely and control sera to asses binding to CD89. Comparison of binding between equal concentrations of serum or that other serum proteins are affecting the binding of IgA to CD89. The advantage of this study compared purified IgA to CD89 revealed a similar level of Polymeric-IgA1 is considered to be a pivotal pathogenic factor In IgAN [1,2] . In contrast, in an experimental model it has been demonstrated that mIgA may protect the glomerulus against immune complexes containing pIgA [17] . In the line of our results this could imply that in patients with IgAN, a reduced binding of mIgA to CD89 might consequently result in a higher chance of binding of pIgA. Heat aggregated myeloma IgA2 (aIgA2) was used for binding to CD89 transfected cells in the absence or presence of mIgA isolated from patients with IgAN or controls. These serum IgA fractions consists for ±85% of IgA1 and therefore will not interfere with our detection system. The result, which is depicted in Figure 6 , shows that indeed mIgA isolated from controls results in a significantly stronger inhibition of the aIgA2 binding, as compared to mIgA from IgAN patients. The fact that we demonstrated a comparable binding to CD89 of IgA1 and IgA2, would also imply an increased deposition of IgA2. However, it is thought that deposits of IgA in IgAN mainly consist of IgA1 [1, 2] .
Binding of IgA-containing immune complexes to mesangial cells induces release of inflammatory factors such as superoxide anion, platelet-activating factor (PAF ), IL-6 and TNF-a [4, 8, 18] . The binding of IgA to mesangial cells is not solely dependent on the presence of CD89. For instance IgA or IgA-containing immune complexes can be bound via their mannose residues and targeted for endocytosis via the mannose receptor [19] . Expression of the mannose receptor on mesangial cells can be upregulated in vitro by TNF-a and IL1-a [19] . Therefore it is most likely that multiple receptors might be responsible for binding of IgA in the kidney. serum IgA concentrations found in IgAN patients leading to the deposition of IgA-IC in the kidney [6, 20] . In addition, also CD89 on mesangial cells might to previous experiments [9] is the more sensitive detection of IgA binding to CD89-transfected cells be involved in clearance of deposited IgA containing immune complexes from the glomeruli, since IgA (Figure 2 ). This difference is most pronounced in the detection of mIgA binding. Using this novel system, a aggregates are taken up and catabolized by mesangial cells over time [18] . Therefore we think it is most likely significantly lower binding to CD89-transfected IIA1.6 cells of mIgA from patients with IgAN as compared that a failure of mesangial clearance could favor accumulation of IgA-IC on mesangial cells and thereby to controls was found. This lower degree of binding to CD89-transfected IIA1.6 cells of mIgA was less promote disease progression.
An aberrant interaction between IgA and its Fc evident for dIgA and pIgA. An explanation why dIgA and pIgA do not show a reduced reactivity with receptor in IgAN patients leading to a defective clearance of IgA might be caused either by a defect in IgA CD89 may be because they react with multiple CD89 molecules on a single cell, which results in an increased or alterations of the Fc receptor. It has been demonstrated that IgA binds to CD89 via its Ca2 and Ca3 avidity. Specific binding of IgA to CD89 could also be detected using U937 cells. However, since this mono-region [21] . Deglycosylation of the N-linked carbohydrate residues in this Ca2 and Ca3 region interrupts cyte like cell line had a ten-fold lower expression of CD89, this resulted in a lower degree of IgA binding. binding to CD89 [21] . In IgAN patients a lack of galactose residues in the O-linked sugars of the IgA1 Nevertheless the same decrease in binding of mIgA in patients as compared to controls was detected.
hinge region has been reported [6, 20, 22, 23] . Since these 9. Reterink TJF, van Zandbergen G, Klar-Mohamad N, et al.
residues are normally recognized by the asialoglycoSize-dependent effect of IgA on the IgA Fc receptor (CD89).
protein receptor, but could also be of importance for 
